Results 91 to 100 of about 8,768 (188)

Endothelin-1 receptors play a minor role in the protection against acute Trypanosoma cruzi infection in mice

Brazilian Journal of Medical and Biological Research, 2007
Chagas' disease, caused by the protozoan Trypanosoma cruzi, is a major cause of cardiovascular disability in countries where it is endemic. Damage to the heart microvasculature has been proposed to be an important factor in the pathogenesis of heart ...
E. Roffê, A.L.S. Souza, P.P. Machado, L.S. Barcelos, A.J. Romanha, F.S. Mariano, J.S. Silva, C.R. Machado, H.B. Tanowitz, M.M. Teixeira   +9 more
doaj  

Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial

BMC Pediatrics
Background Access to inhaled nitric oxide (iNO) is limited in low resource settings due to non-availability and high cost. There is a need for research on low-cost alternative therapies for management of persistent pulmonary hypertension of the newborn ...
Aditya Kallimath, Sujata Deshpande, Pari Singh, Reema Garegrat, Satyan Lakshminrusimha, Rajesh Maheshwari, Pradeep Suryawanshi   +6 more
doaj   +1 more source

Funding Linked to Ongoing Research: Impact of the Bosentan Patient Registry on Pricing in Australia

, 2011
ObjectivesBosentan, a dual endothelin receptor antagonist (ERA), was the first oral drug approved for the treatment of pulmonary arterial hypertension (PAH), a rare disease with poor prognosis.
Reid, Christopher, Pater, G., Christopher M. Reid, Wlodarczyk, J., Pater, Glen, John Wlodarczyk, Wlodarczyk, John, Reid, Christopher M., Glen Pater   +8 more
core   +1 more source

Early Administration of Bosentan in High‐Risk COVID‐19 Outpatients at Risk of Sarcopenia: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Journal of Cachexia, Sarcopenia and Muscle
Background Endothelial damage induces myofibrillar breakdown and muscle degradation in COVID‐19 infection. There is a relationship between increased endothelin‐1 synthesis and sarcopenia. We evaluated the preventive effect of early bosentan therapy as an
Shaahin Shahbazi, Erfan Shahbazi, Farid Zayeri, Zahra Vahdat Shariatpanahi   +3 more
doaj   +1 more source

Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension

, 2005
ObjectivesThis study investigated the long-term outcome of children with pulmonary arterial hypertension (PAH) treated with bosentan therapy, with or without concomitant prostanoid therapy.BackgroundBosentan, an oral endothelin ETA/ETBreceptor antagonist,
Doran, Aimee, Widlitz, Allison, Abman, Steven H., Yung, Delphine, Nguyen, Ngoc, Barst, Robyn J., Ivy, D. Dunbar, Claussen, Lori R., Rosenzweig, Erika Berman, Morganti, Adele   +9 more
core   +1 more source

Abstracts From PVRI 2026 Dublin

Pulmonary Circulation, Volume 16, Issue 2, June 2026.
wiley   +1 more source

What is the role of bosentan in healing of femur fractures in a rat model?

, 2015
The purpose of this study was to examine the effects bosentan (which is a strong vasoconstrictor) on bone fracture pathophysiology, and investigate the roles of the nonselective endothelin 1 receptor blocker bosentan on the bone fractures formed in rats ...
Muhammed Yayla, A. Murat Aksakal, HALICI, Zekai, AYDIN, Ali, S. Sena Karcioglu, KARCIOGLU, S. Sena, AKSAKAL, A. Murat, Kunak, C. Semih, Saritemur, Murat, Murat Saritemur, Atmaca, H. Tarik, Zekai Halici, YAYLA, Muhammed, AKPINAR, Erol, ÇADIRCI, Elif, H. Tarik Atmaca, C. Semih Kunak, Elif Cadirci, Erol Akpinar, Ali Aydin   +19 more
core   +1 more source

Select Abstracts From the 19th International Conference on Neonatal and Childhood Pulmonary Vascular Disease

Pulmonary Circulation, Volume 16, Issue 2, June 2026.
wiley   +1 more source

Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan

, 2002
Background/Aims: Bosentan, a dual endothelin ETA/B receptor antagonist, may cause dose-dependent reversible cholestatic liver injury. We herein tested whether bosentan or metabolites, both eliminated in bile, induce alterations in bile secretion. Methods:
Lasnier, Elisabeth, Kinnman, Nils, Poupon, Raoul, Housset, Chantal, Elferink, Ronald P. J. Oude, Lefèvre, Guillaume, Fouassier, Laura, Rey, Colette   +7 more
core   +1 more source

Bosentan in pediatric patients with pulmonary arterial hypertension

, 2009
OBJECTIVE: In order to provide an overview of current knowledge, the literature was systematically examined for clinical studies, which evaluate the safety and effectiveness of bosentan in pediatric pulmonary arterial hypertension (PAH).
Beghetti, Maurice
core